相关临床试验
31
30 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
进行中（未招募）
30
96.8%
已完成
1
3.2%
暂无批准数据
- GSK has secured full global rights to Chimagen Biosciences' unnamed trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. - The preclinical asset is designed to bind T cells while targeting two tumor-associated antigens, aiming for deeper responses and better tolerability than existing engagers. - GSK plans to begin Phase 1 testing in 2027, adding to a myeloma portfolio anchored by the BCMA-directed antibody-drug conjugate Blenrep. - The deal is GSK's second with Chimagen, following the 2024 licensing of the CD19/CD20-targeted T-cell engager CMG1A46 for B-cell malignancies and autoimmune disease.
- Sonoma Biotherapeutics has appointed Stephen Dilly, MBBS, PhD, as its new President and CEO, replacing co-founder Jeff Bluestone who transitions to an advisory role. - The leadership change follows positive interim safety and efficacy results from the company's first-in-human study of SBT-77-7101 in patients with refractory rheumatoid arthritis. - Dr. Dilly brings nearly 40 years of biopharmaceutical experience and has been associated with the development, approval and launch of more than 25 marketed drugs. - The company is developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, with a collaboration pipeline including Regeneron.
- ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, replacing Dr. Alan Sandler who will return to the company's Board of Directors. - Dr. Klencke brings over 30 years of experience in oncology drug development, including leadership roles at Sierra Oncology, Onyx Pharmaceuticals, and Genentech. - The appointment aims to accelerate development of ALX Oncology's pipeline, including evorpacept, a CD47 blocker in multiple clinical trials, and ALX2004, an EGFR-targeted antibody-drug conjugate that entered Phase 1 trials in August 2025. - Dr. Klencke previously served on ALX Oncology's Board of Directors since January 2025 and has witnessed the progress of both clinical programs firsthand.
• Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies. • The fund has previously backed companies that achieved significant milestones, including FDA approvals for treatments targeting COPD, myelodysplastic syndrome, narcolepsy, and Prader-Willi Syndrome. • Several Vivo-backed companies have been acquired by pharmaceutical giants in billion-dollar deals, including RayzeBio (Bristol-Myers Squibb, $4.1B), Chinook Therapeutics (Novartis, $3.2B), and Sierra Oncology (GSK, $1.9B).
- GSK's JAK inhibitor Ojjaara (momelotinib) receives FDA approval for both newly diagnosed and previously treated myelofibrosis patients with anemia, surpassing expected second-line only indication. - The drug demonstrated significant benefits in the MOMENTUM trial, with 31% of patients achieving transfusion independence at week 24 compared to 20% in the control group. - Ojjaara addresses multiple disease manifestations including anemia, constitutional symptoms, and splenomegaly, offering a new treatment option where current therapies often worsen anemia.
- Health Canada has approved GSK's Ojjaara (momelotinib) for treating myelofibrosis (MF) in adult patients with moderate-to-severe anemia. - The approval is based on Phase III MOMENTUM trial data, which showed improvements in symptom score, transfusion independence, and splenic response rate compared to danazol. - Ojjaara, a once-daily oral treatment, is indicated for intermediate or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF. - This approval provides a new treatment option for Canadian patients with myelofibrosis-related anemia, addressing a critical unmet need in hematology oncology.
- The FDA has delayed its decision on GSK's momelotinib, a potential treatment for myelofibrosis, to September 16 to review additional data. - Momelotinib, acquired through GSK's $2 billion purchase of Sierra Oncology, aims to alleviate symptoms like anemia and reduce transfusion needs in myelofibrosis patients. - The drug targets a different protein than existing JAK inhibitors like Jakafi, offering a potential new option for patients who don't respond well to current treatments. - Analysts speculate the additional data may support a broader use of momelotinib, although Jakafi is expected to remain the preferred first-line treatment.
